These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 9809795

  • 1. Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a beta-strand/loop/beta-strand structure secured by hydrophobic interactions and predictive of activity.
    Tsigelny I, Mahata SK, Taupenot L, Preece NE, Mahata M, Khan I, Parmer RJ, O'Connor DT.
    Regul Pept; 1998 Oct 16; 77(1-3):43-53. PubMed ID: 9809795
    [Abstract] [Full Text] [Related]

  • 2. Interaction of the catecholamine release-inhibitory peptide catestatin (human chromogranin A(352-372)) with the chromaffin cell surface and Torpedo electroplax: implications for nicotinic cholinergic antagonism.
    Taupenot L, Mahata SK, Mahata M, Parmer RJ, O'Connor DT.
    Regul Pept; 2000 Nov 24; 95(1-3):9-17. PubMed ID: 11062327
    [Abstract] [Full Text] [Related]

  • 3. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity.
    Mahata SK, Mahata M, Wakade AR, O'Connor DT.
    Mol Endocrinol; 2000 Oct 24; 14(10):1525-35. PubMed ID: 11043569
    [Abstract] [Full Text] [Related]

  • 4. Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A.
    Preece NE, Nguyen M, Mahata M, Mahata SK, Mahapatra NR, Tsigelny I, O'Connor DT.
    Regul Pept; 2004 Apr 15; 118(1-2):75-87. PubMed ID: 14759560
    [Abstract] [Full Text] [Related]

  • 5. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters.
    Mahapatra NR, Mahata M, Mahata SK, O'Connor DT.
    J Hypertens; 2006 May 15; 24(5):895-904. PubMed ID: 16612252
    [Abstract] [Full Text] [Related]

  • 6. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist.
    Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ.
    J Clin Invest; 1997 Sep 15; 100(6):1623-33. PubMed ID: 9294131
    [Abstract] [Full Text] [Related]

  • 7. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance.
    Mahata SK, Mahata M, Parmer RJ, O'Connor DT.
    J Biol Chem; 1999 Jan 29; 274(5):2920-8. PubMed ID: 9915830
    [Abstract] [Full Text] [Related]

  • 8. The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses.
    Mahata SK, Mahata M, Wen G, Wong WB, Mahapatra NR, Hamilton BA, O'Connor DT.
    Mol Pharmacol; 2004 Nov 29; 66(5):1180-91. PubMed ID: 15326220
    [Abstract] [Full Text] [Related]

  • 9. Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin.
    Mahata SK, Mahapatra NR, Mahata M, Wang TC, Kennedy BP, Ziegler MG, O'Connor DT.
    J Biol Chem; 2003 Aug 22; 278(34):32058-67. PubMed ID: 12799369
    [Abstract] [Full Text] [Related]

  • 10. A novel, catecholamine release-inhibitory peptide from chromogranin A: autocrine control of nicotinic cholinergic-stimulated exocytosis.
    Mahata SK, Mahata M, Yoo SH, Taupenot L, Wu H, Aroda VR, Livsey CV, Taulane JP, Goodman M, Parmer RJ, O'Connor DT.
    Adv Pharmacol; 1998 Aug 22; 42():260-4. PubMed ID: 9327894
    [No Abstract] [Full Text] [Related]

  • 11. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules.
    Taylor CV, Taupenot L, Mahata SK, Mahata M, Wu H, Yasothornsrikul S, Toneff T, Caporale C, Jiang Q, Parmer RJ, Hook VY, O'Connor DT.
    J Biol Chem; 2000 Jul 28; 275(30):22905-15. PubMed ID: 10781584
    [Abstract] [Full Text] [Related]

  • 12. Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells.
    Lee JC, Taylor CV, Gaucher SP, Toneff T, Taupenot L, Yasothornsrikul S, Mahata SK, Sei C, Parmer RJ, Neveu JM, Lane WS, Gibson BW, O'Connor DT, Hook VY.
    Biochemistry; 2003 Jun 17; 42(23):6938-46. PubMed ID: 12795588
    [Abstract] [Full Text] [Related]

  • 13. Modulatory mechanism of the endogenous peptide catestatin on neuronal nicotinic acetylcholine receptors and exocytosis.
    Herrero CJ, Alés E, Pintado AJ, López MG, García-Palomero E, Mahata SK, O'Connor DT, García AG, Montiel C.
    J Neurosci; 2002 Jan 15; 22(2):377-88. PubMed ID: 11784782
    [Abstract] [Full Text] [Related]

  • 14. Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin.
    Biswas N, Vaingankar SM, Mahata M, Das M, Gayen JR, Taupenot L, Torpey JW, O'Connor DT, Mahata SK.
    Endocrinology; 2008 Feb 15; 149(2):749-57. PubMed ID: 17991725
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo.
    Kennedy BP, Mahata SK, O'Connor DT, Ziegler MG.
    Peptides; 1998 Feb 15; 19(7):1241-8. PubMed ID: 9786174
    [Abstract] [Full Text] [Related]

  • 16. The novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364). Properties and function.
    Mahata SK, Mahata M, Livsey Taylor CV, Taupenot L, Parmer RJ, O'Connor DT.
    Adv Exp Med Biol; 2000 Feb 15; 482():263-77. PubMed ID: 11192587
    [No Abstract] [Full Text] [Related]

  • 17. New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A.
    Briolat J, Wu SD, Mahata SK, Gonthier B, Bagnard D, Chasserot-Golaz S, Helle KB, Aunis D, Metz-Boutigue MH.
    Cell Mol Life Sci; 2005 Feb 15; 62(3):377-85. PubMed ID: 15723172
    [Abstract] [Full Text] [Related]

  • 18. Molecular interactions of the physiological anti-hypertensive peptide catestatin with the neuronal nicotinic acetylcholine receptor.
    Sahu BS, Mohan J, Sahu G, Singh PK, Sonawane PJ, Sasi BK, Allu PK, Maji SK, Bera AK, Senapati S, Mahapatra NR.
    J Cell Sci; 2012 May 01; 125(Pt 9):2323-37. PubMed ID: 22357947
    [Abstract] [Full Text] [Related]

  • 19. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension.
    O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ.
    J Hypertens; 2002 Jul 01; 20(7):1335-45. PubMed ID: 12131530
    [Abstract] [Full Text] [Related]

  • 20. A molecular dynamics study of catestatin docked on nicotinic acetylcholine receptors to identify amino acids potentially involved in the binding of chromogranin A fragments.
    Kraszewski S, Drabik D, Langner M, Ramseyer C, Kembubpha S, Yasothornsrikul S.
    Phys Chem Chem Phys; 2015 Jul 14; 17(26):17454-60. PubMed ID: 26079001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.